Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists

被引:22
作者
Cid-Jofre, Valeska [1 ]
Moreno, Macarena [1 ,2 ]
Reyes-Parada, Miguel [1 ,3 ]
Renard, Georgina M. [1 ]
机构
[1] Univ Santiago Chile USACH, Fac Ciencias Med, Escuela Med, Ctr Invest Biomed & Aplicada CIBAP, Santiago 9170022, Chile
[2] Univ Bernardo OHiggins, Escuela Psicol, Fac Ciencias Sociales, Santiago 8370993, Chile
[3] Univ Autonoma Chile, Fac Ciencias Salud, Providencia 7500912, Chile
关键词
neuropeptides; oxytocin; vasopressin; pharmacology; antagonists; agonists; neuropsychiatry disorders; MESSENGER-RNA LEVELS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CORTICOTROPIN-RELEASING HORMONE; NUCLEUS-ACCUMBENS OXYTOCIN; V-1B RECEPTOR ANTAGONIST; ANXIETY-RELATED BEHAVIOR; MULTIPLE BINDING-SITES; ARGININE-VASOPRESSIN; AGGRESSIVE-BEHAVIOR; MATERNAL-BEHAVIOR;
D O I
10.3390/ijms222112077
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxytocin (OT) and vasopressin (AVP) are hypothalamic neuropeptides classically associated with their regulatory role in reproduction, water homeostasis, and social behaviors. Interestingly, this role has expanded in recent years and has positioned these neuropeptides as therapeutic targets for various neuropsychiatric diseases such as autism, addiction, schizophrenia, depression, and anxiety disorders. Due to the chemical-physical characteristics of these neuropeptides including short half-life, poor blood-brain barrier penetration, promiscuity for AVP and OT receptors (AVP-R, OT-R), novel ligands have been developed in recent decades. This review summarizes the role of OT and AVP in neuropsychiatric conditions, as well as the findings of different OT-R and AVP-R agonists and antagonists, used both at the preclinical and clinical level. Furthermore, we discuss their possible therapeutic potential for central nervous system (CNS) disorders.
引用
收藏
页数:29
相关论文
共 224 条
[1]  
Abbott Gmbh Co. KG., 2014, U.S. Patent, Patent No. 0322809
[2]  
Abbott Gmbh Co. KG., 2013, U.S. Patent, Patent No. 8580842
[3]  
AbbVie Deutschland GmbH Co. KG., 2014, U.S. Patent, Patent No. 8629148
[4]  
AbbVie Deutschland GmbH Co. KG., 2013, U.S. Patent, Patent No. 8546401
[5]   Oxytocin receptor antagonist atosiban impairs consolidation, but not reconsolidation of contextual fear memory in rats [J].
Abdullahi, Payman Rasie ;
Eskandarian, Sharaf ;
Ghanbari, Ali ;
Rashidy-Pour, Ali .
BRAIN RESEARCH, 2018, 1695 :31-36
[6]   Oxytocin and estrogen receptor β in the brain: an overview [J].
Acevedo-Rodriguez, Alexandra ;
Mani, Shaila K. ;
Handa, Robert J. .
FRONTIERS IN ENDOCRINOLOGY, 2015, 6
[7]   REGULATION OF PITUITARY VASOPRESSIN RECEPTORS DURING CHRONIC STRESS - RELATIONSHIP TO CORTICOTROPH RESPONSIVENESS [J].
AGUILERA, G ;
PHAM, QC ;
RABADANDIEHL, C .
JOURNAL OF NEUROENDOCRINOLOGY, 1994, 6 (03) :299-304
[8]   Amphetamine treatment affects the extra-hypothalamic vasopressinergic system in a sex- and nucleus-dependent manner [J].
Ahumada, C. ;
Bahamondes, C. ;
Cerda, C. A. ;
Silva, R. A. ;
Cruz, G. ;
Moya, P. R. ;
Sotomayor-Zarate, R. ;
Renard, G. M. .
JOURNAL OF NEUROENDOCRINOLOGY, 2017, 29 (04)
[9]   Species, sex and individual differences in the vasotocin/vasopressin system: Relationship to neurochemical signaling in the social behavior neural network [J].
Albers, H. Elliott .
FRONTIERS IN NEUROENDOCRINOLOGY, 2015, 36 :49-71
[10]   Determining the structure and binding mechanism of oxytocin-Cu2+ complex using paramagnetic relaxation enhancement NMR analysis [J].
Alshanski, Israel ;
Shalev, Deborah E. ;
Yitzchaik, Shlomo ;
Hurevich, Mattan .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2021, 26 (07) :809-815